Literature DB >> 31073701

[Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months.]

Dirk Böhmer1, Felix Sedlmayer2, Thomas Wiegel3, Frank Wolf4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31073701     DOI： 10.1007/s00066-019-01470-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.

Authors:  Pirus Ghadjar; Thomas Wiegel
Journal:  Eur Urol       Date:  2018-10-26       Impact factor: 20.096

2.  Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.

Authors:  Abdenour Nabid; Nathalie Carrier; André-Guy Martin; Jean-Paul Bahary; Céline Lemaire; Sylvie Vass; Boris Bahoric; Robert Archambault; François Vincent; Redouane Bettahar; Marie Duclos; Marie-Pierre Garant; Luis Souhami
Journal:  Eur Urol       Date:  2018-07-03       Impact factor: 20.096

3.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Authors:  Michel Bolla; Geertjan Van Tienhoven; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Ignace Billiet; José Lopez Torecilla; Raphael Pfeffer; Carmel Lino Cutajar; Theodore Van der Kwast; Laurence Collette
Journal:  Lancet Oncol       Date:  2010-10-07       Impact factor: 41.316

4.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

5.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Authors:  Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.